Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions.

Author information

Affiliations

  • 1. Department of Psychiatry, Mount Sinai School of Medicine and Bronx VA Medical Center, NY 10468, USA.
      Authors
    • Haroutunian V 1
    (1 author)

Brain research. Molecular Brain Research, 01 Jun 1997, 46(1-2):161-168
https://doi.org/10.1016/s0169-328x(96)00297-5 PMID: 9191090 

Abstract 

Abnormal deposition and accumulation of Alzheimer's amyloid beta-protein (A beta) and degeneration of forebrain cholinergic neurons are among the principal features of Alzheimer's disease. Studies in rat model systems have shown that forebrain cholinergic deficits are accompanied by induction of cortical beta-amyloid precursor protein (beta-APP) mRNAs and increased levels of secreted beta-APP in the CSF. The studies reported here determined whether the CSF levels of secreted beta-APP could be altered pharmacologically. In different experiments, rats with lesions of the forebrain cholinergic system received injections of vehicle, a muscarinic receptor antagonist scopolamine, or one of two cholinesterase inhibitors - diisopropyl phosphorofluoridate (DFP) or phenserine. Scopolamine was administered to determine whether the levels of beta-APP in the CSF could be increased by anticholinergic agents. The cholinesterase inhibitors were administered to determine whether the forebrain cholinergic system lesion-induced increases in CSF beta-APP could be reduced by cholinergic augmentation. Scopolamine administration led to a significant increase in the CSF levels of secreted beta-APP in sham-lesioned rats. Phenserine, a novel, reversible acetyl-selective cholinesterase inhibitor, significantly decreased the levels of secreted beta-APP in the CSF of forebrain cholinergic system-lesioned rats whereas DFP, a relatively non-specific cholinesterase inhibitor, failed to affect CSF levels of secreted beta-APP. These results suggest that the levels of secreted beta-APP in the CSF can be pharmacologically modulated but that this modulation is dependent upon the status of the forebrain cholinergic system and the pharmacological properties of the drugs used to influence it.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/s0169-328x(96)00297-5

References 

Articles referenced by this article (59)

  • Anderson, J., Wallace, W., Snyder, S., Haroutunian, V., Roberts, J.L. and Lieberburg, I., Cellular forms of the rat and human beta-amyloid precursor protein (BAPP), Brain Res., 478 (1989) 391–398.
  • Anderson, J.P., Chen, Y., Kim, K.S. and Robakis, N.K., An alternative secretase cleavage produces soluble Alzheimer amyloid precursor protein containing a potentially amyloidogenic sequence, J. Neurochem., 59 (1992) 2328–2331.
  • Beeson, J., Shelton, E., Chan, H. and Gage, F., Age and damage induced changes in amyloid protein precursor immunohistochemistry in the rat brain, Comp. Neurol., 342 (1994) 69–77.
  • Beller, S.A., Overall, J.E., Rhoades, H.M. and Swann, A.C., Long-term outpatient treatment of senile dementia with oral physostigmine, J. Clin. Psychiatry, 49 (1988) 400–404.
  • Bierer, L., Haroutunian, V., Gabriel, S., Knott, P., Carlin, L., Dushyant, P., Perl, D., Schmeidler, J., Kanof, P. and Davis, K., Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits, J. Neurochem., 64 (1995) 749–760.
  • Blozovski, D. and Hennocq, N., Effects of antimuscarinic cholinergic drugs injected systemically or into the hippocampo-entorhinal area upon passive avoidance learning in young rats, Psychopharmacology, 76 (1982) 351–358.
  • Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding, Anal. Biochem., 72 (1976) 248–254.
  • Brzostowska, M., He, X.S., Greig, N.H., Rapaport, S. and Brossi, A., Selective inhibition of acetyl- and butyrylcholinesterases by phenylcarbamates of (−)-eseroline, (−)-(N1)-noreseroline and physovenol, Med. Chem. Res., 2 (1992) 238–246.
  • Buxbaum, J., Oishi, M., Chen, H., Pinkas-Kramarski, R., Jaffe, E., Gandy, S. and Greengard, P., Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer B/A4 amyloid protein precursor, Proc. Natl. Acad. Sci. USA, 89 (1992) 10075–10078.
  • Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A.Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I. and Selkoe, D.J., Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production, Nature (London), 360 (1992) 672–674.
Show 10 more references (10 of 59)

Citations & impact 

Impact metrics

39
Citations
Jump to Citations

Citations of article over time

Article citations

Go to all (39) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

NIA NIH HHS (1)